Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

Published:2022-06 Issue:3 Volume:7 Page:100510
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Tombal B.^ORCID,Sternberg C.N.,Hussain M.,Ganguli A.,Li Y.,Sandin R.,Bhadauria H.,Oh M.,Saad F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial;Bolla;Lancet,2002

3. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions;Lawton;Int J Radiat Oncol Biol Phys,2007

4. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate;Pilepich;Int J Radiat Oncol Biol Phys,2001

5. Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy;Spratt;Prostate,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors;Molecular and Clinical Oncology;2024-08-08

2. Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study;European Journal of Cancer;2023-12